Nanotechnology-Enhanced Controlled Release Systems in Topical Therapeutics DOI Creative Commons

Yohannes Teklehaimanot

Precision Nanomedicine, Journal Year: 2024, Volume and Issue: 7(4)

Published: Dec. 11, 2024

<img src=” https://s3.amazonaws.com/production.scholastica/article/127336/large/prnano_1672024ga.jpg?1733950699”> Topical and transdermal drug delivery are alternative routes for medications facing challenges like solubility, stability, first-pass metabolism. However, conventional immediate-release dosage forms delivered topically have drawbacks, including poor penetration high side ef-fects. Controlled-release nanoparticles offer a promising solution, improving permeation providing controlled release. This review examines recent advances, challenges, prospects of controlled-release topical delivery. Various types nanoparticles, lipid nanoemulsions, nanoemulgels, cubosome liposomes, poly-meric solid-lipid lipid-polymer hybrid nanostructured carriers, carbon nanotubes, nanocomposites, protein been explored their ability to encapsulate drugs, prolong release, enhance skin as well improve therapeutic outcomes. Studies demonstrated the effectiveness these in sustained wide range poorly soluble, low degree penetration, drugs with bioavailability biological products. Despite potential benefits, such scalability, reproducibility, safety concerns remain. Future research should ad-dress explore novel strategies efficacy by converging microneedles 3D nanoparticles. Ultimately, revolutionize dermatological delivery, leading improved outcomes patient care.

Language: Английский

Development of 5-fluorouracil/etoposide co-loaded electrospun nanofibrous scaffold for localized anti-melanoma therapy DOI Creative Commons
Shirin Shojaei, Mahtab Doostan,

Hamid-Reza Mohammadi Motlagh

et al.

Journal of Applied Biomaterials & Functional Materials, Journal Year: 2024, Volume and Issue: 22

Published: Jan. 1, 2024

Nanofibrous scaffolds have emerged as promising candidates for localized drug delivery systems in the treatment of cutaneous cancers. In this study, we prepared an electrospun nanofibrous scaffold incorporating 5-fluorouracil (5-FU) and etoposide (ETP) chemotherapy targeting melanoma cancer. The was composed polyvinyl alcohol (PVA) chitosan (CS), via electrospinning process loaded with chemotherapeutic agents. We conducted relevant physicochemical characterizations, assessed cytotoxicity, evaluated apoptosis against A375 cells. 5-FU/ETP co-loaded PVA/CS exhibited nanofibers (NFs) average diameter 321 ± 61 nm, defect-free homogenous morphology. FTIR spectroscopy confirmed successful incorporation chemotherapeutics into scaffold. Additionally, demonstrated a hydrophilic surface, proper mechanical strength, high porosity, efficient liquid absorption capacity. Notably, sustained controlled release observed from Furthermore, significantly increased cytotoxicity (95%) (74%) Consequently, holds promise valuable system eradication tumors mitigation adverse reactions associated chemotherapy.

Language: Английский

Citations

3
Comparative efficacy of topical 10% versus 5% tranexamic acid in treatment of women with melasma: a double-blind randomized controlled trial DOI Creative Commons
Ferra O. Mawu, Marlyn G. Kapantow, Herry E. J. Pandaleke

et al.

Universa Medicina, Journal Year: 2024, Volume and Issue: 43(2), P. 213 - 219

Published: Aug. 12, 2024

BackgroundMelasma is a highly prevalent chronic pigmentary disorder. The pathogenesis unknown but melasma often occurs in photo-exposed areas, e.g., cheeks, upper lip, chin, and forehead. Tranexamic acid (TA), plasmin inhibitor, aids the inhibition of UV-induced activity melanogenesis, making it favorable therapeutic option for melasma. may be administered through various routes, topical. This study aimed to compare efficacy topical 10% versus 5% TA women with MethodsThis double-blind randomized controlled trial included 16 females epidermal type who were into two groups receive either (n = 8) or applied twice daily eight weeks. Prior intervention at 8 weeks after intervention, intensity extension assessed based on area severity index (MASI) score pigmentation score. ResultsMean MASI scores both treatment similar base-line (p>0.05). reduction was statistically not significant 4 There no drug-related adverse reactions complications. ConclusionThis demonstrated that effective treating utilization promising alternative without need increase concentration formulation.

Language: Английский

Citations

1
Material informatics-driven insights into brain cancer nanocarriers: A bibliometric comparison of PLGA vs. liposomes DOI Creative Commons

Brilly Andro Makalew,

Syauqi Abdurrahman Abrori

OpenNano, Journal Year: 2024, Volume and Issue: 21, P. 100225 - 100225

Published: Dec. 11, 2024

Language: Английский

Citations

1
Betamethasone Dipropionate Loaded in Nanoliposomes vs Conventional Betamethasone Dipropionate: Comparative Study of Permeability and Penetrability <i>in </i><i>Vitro</i> and <i>ex </i><i>Vivo</i> DOI Open Access
Carmen Rodrı́guez,

Adriana Camino,

Anyoli Taly

et al.

Journal of Biosciences and Medicines, Journal Year: 2024, Volume and Issue: 12(10), P. 140 - 156

Published: Jan. 1, 2024

Language: Английский

Citations

0
Can Carotenoid Encapsulated Hydrogel Be a Promising Medium for Repairing Skin Damage DOI
Daiji Brahma, Debjani Dutta, Pradeep Das

et al.

Regenerative Engineering and Translational Medicine, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 18, 2024

Language: Английский

Citations

0
Toxicity and Dermatokinetic Analysis of Ibrutinib in Human Skin Models DOI Creative Commons
Maria Victória Souto-Silva, Elizabete Cristina Iseke Bispo, Lucas F. F. Albuquerque

et al.

Pharmaceutics, Journal Year: 2024, Volume and Issue: 16(11), P. 1377 - 1377

Published: Oct. 26, 2024

Background/Objectives: Ibrutinib (IBR) is a tyrosine kinase inhibitor under investigation in preclinical and clinical settings as an alternative treatment for melanoma. Nevertheless, the limited oral bioavailability of IBR need high doses drug to kill melanoma cells are major drawbacks this purpose. Considering that restricted skin at early stages, topical application might constitute effective safer administration route. In study, we determined IBR’s toxicity dermatokinetics using human primary organotypic explant cultures (hOSECs). Methods: After demonstrating fibroblasts keratinocytes present target genes, cytotoxicity was MTT annexin V/PI staining assays. assessed TTC assay, irritation potential established histological assessment. Finally, cutaneous permeation ex vivo determine dermatokinetics. Results: Our findings reveal exerts dose-dependent towards cells, presenting IC50 same range cells. The successfully reduced skin, shown permeate stratum corneum reach viable layers therapeutic concentrations. Conclusions: Overall, our data encourage treat melanoma, paving way future studies theme.

Language: Английский

Citations

0
Nanotechnology-Enhanced Controlled Release Systems in Topical Therapeutics DOI Creative Commons

Yohannes Teklehaimanot

Precision Nanomedicine, Journal Year: 2024, Volume and Issue: 7(4)

Published: Dec. 11, 2024

<img src=” https://s3.amazonaws.com/production.scholastica/article/127336/large/prnano_1672024ga.jpg?1733950699”> Topical and transdermal drug delivery are alternative routes for medications facing challenges like solubility, stability, first-pass metabolism. However, conventional immediate-release dosage forms delivered topically have drawbacks, including poor penetration high side ef-fects. Controlled-release nanoparticles offer a promising solution, improving permeation providing controlled release. This review examines recent advances, challenges, prospects of controlled-release topical delivery. Various types nanoparticles, lipid nanoemulsions, nanoemulgels, cubosome liposomes, poly-meric solid-lipid lipid-polymer hybrid nanostructured carriers, carbon nanotubes, nanocomposites, protein been explored their ability to encapsulate drugs, prolong release, enhance skin as well improve therapeutic outcomes. Studies demonstrated the effectiveness these in sustained wide range poorly soluble, low degree penetration, drugs with bioavailability biological products. Despite potential benefits, such scalability, reproducibility, safety concerns remain. Future research should ad-dress explore novel strategies efficacy by converging microneedles 3D nanoparticles. Ultimately, revolutionize dermatological delivery, leading improved outcomes patient care.

Language: Английский

Citations

0